Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial

1. VOR priced a public offering of 10 million shares at $10 each. 2. The Phase 3 study for telitacicept reached its primary endpoint. 3. Significant reductions in proteinuria compared to placebo were observed. 4. Telitacicept showed benefits across secondary endpoints and good safety profile. 5. VOR's stock is down 44.31% following the pricing announcement.